02:53 AM EDT, 08/07/2026 (MT Newswires) -- Oxford Biomedica (OXB.L) said Friday its revenue grew 9% year over year for the six months ended June 30 to 80 million pounds sterling. For 2026, the cell and gene therapy company now forecasts revenue of between 180 million pounds and 200 million pounds, against the previous forecast of 220 million pounds to 240 million pounds. Looking further ahead, the company maintained its target of 25% to 30% revenue growth for 2027.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.